GC Green Cross MS has received permission from the Ministry of Food and Drug Safety to export their dengue virus rapid diagnostic kit, including the ‘GENEDIA W Dengue NS1 Ag’ antigen test and ‘GENEDIA W Dengue IgM/IgG Ab’ antibody test. This diagnostic kit can diagnose dengue fever within 20 minutes using a blood sample and has shown higher sensitivity and accuracy compared to other companies. The kit is important for diagnosing dengue fever, which is a viral febrile disease transmitted by Aedes aegypti mosquitoes. The company expects an increase in sales due to the rising number of dengue virus infections globally, especially in Southeast Asia and South America. GC Green Cross MS is also working on developing diagnostic kits for other mosquito-borne infectious diseases.
In other news, Bukwang Pharmaceutical has applied for the registration of drug insurance benefits for their new drug, Latuda Tablet, which is used for the treatment of schizophrenia and bipolar depression type 1. The company aims to provide prompt treatment opportunities for patients by advancing the timing of drug insurance coverage decisions. If approved, Latuda Tablet has the potential to become a popular treatment option based on its efficacy, safety, and clinical trial results. Bukwang Pharmaceutical is focused on strengthening their central nervous system product line portfolio.
Lastly, the ‘Korea Pharmaceutical and Bio Job Fair 2023’, hosted by several organizations including the Korea Pharmaceutical and Biotechnology Association, will be held on the 19th. The job fair aims to connect job seekers with pharmaceutical and bio companies, offering recruitment booths and various consultation and mentoring programs. The fair will also have an online recruitment center available until December 31st.
◇ GC Green Cross dengue virus rapid diagnostic kit, approved for export
▲ GC Green Cross MS obtained permission from the Ministry of Food and Drug Safety to export the dengue virus rapid diagnostic kit ‘GENEDIA W Dengue NS1 Ag’ antigen test and antibody test ‘GENEDIA W Dengue IgM/IgG Ab’.
GC Green Cross MS (CEO Sakong Young-hee) announced on the 18th that it has received export approval for the dengue virus rapid diagnostic kit ‘GENEDIA W Dengue NS1 Ag’ antigen test and antibody test ‘GENEDIA W Dengue IgM/IgG’ Ab’ from the Ministry of Food and Drug Safety. .
The dengue fever diagnostic kit developed this time applies similar principles to the COVID-19 rapid diagnostic kit familiar to users.
It can diagnose dengue fever within 20 minutes through a blood sample and is characterized by the ability to diagnose all four dengue virus serotypes. In in-house clinical sample testing, we confirmed higher sensitivity and accuracy compared to other companies.
Dengue fever, like Zika virus, is a representative viral febrile disease transmitted by Aedes aegypti mosquitoes, mainly in tropical and subtropical regions.
A differential diagnosis is necessary because the symptoms are similar to other mosquito-borne diseases such as chikungunya. Recently, with the acceleration of global warming and climate change, the risk of the international spread of mosquito-borne diseases has increase, so the importance of quarantine and diagnosis increases..
A company official said, “With the number of infected people worldwide increasing rapidly due to the recent spread of the dengue virus, a mosquito-borne disease, mainly in Southeast Asia and South America, we expect a rapid increase in sales in the mosquito-borne virus diagnostic kit market by obtaining this export license.” “Follow-on product development for mosquito-borne infectious diseases other than dengue fever is underway,” he said.
◇ Bukwang Pharmaceutical applies to register insurance benefits for ‘Latuda Tablet’, a new drug for the treatment of schizophrenia and bipolar depression type 1
Bukwang Pharmaceutical announced that it has applied for the registration of drug insurance benefits for Latuda Tablet (ingredient name: Lurasidone), a new drug for the treatment of schizophrenia and bipolar depression type 1.
Bukwang Pharmaceutical applied for product approval for Latuda Tablet on October 31 last year. At the time of the application, it applied for a review related to drug approval and insurance benefit evaluation as a new drug, and applied for an insurance benefit list as the Ministry of Food and the Drug Safety effectiveness review was recently completed. He explained that he was doing it.
The accompanying review of drug approval and insurance benefits evaluation is designed to provide prompt treatment opportunities for patients by advancing the timing of drug insurance coverage decisions by enabling requests for nursing care benefit decisions even before drug approval, and after the completion of the Administration Food and Drug Safety Review for safety and effectiveness This is a system that allows pharmaceutical companies to apply to the HIRA for a decision on nursing care benefits.
Once the nursing care benefits evaluation has been completed with the Health Insurance Review and Assessment Service, final reimbursement and drug prices are determined through drug price negotiations with the National Health Insurance Corporation.
Ratuda is an atypical antipsychotic drug developed by Japan’s Sumitomo Pharma and approved for the treatment of schizophrenia and bipolar depression type 1. Bukwang Pharmaceutical has been granted exclusive licensing rights in Korea since April 2017, and has development rights and exclusive distribution. .
According to Bukwang Pharmaceutical, Latuda Tablet is approved as a treatment for schizophrenia in adults in 53 countries, including the United States and the European Union, and in some countries, it is also approved as a treatment for schizophrenia in young people (13 to 17 years).
In addition, it is approved in 20 countries, including the United States, as monotherapy and as adjunctive therapy to lithium or valproic acid for depressive episodes of bipolar 1 disorder (bipolar depression) in adults, and in some countries in children (10). to age 17) It is also approved as monotherapy for depressive episodes in bipolar 1 disorder (bipolar depression).
Bukwang Pharmaceutical said, “If lurasidone is approved in Korea, it is expected to become a welcome treatment option for patients with schizophrenia and bipolar depression type 1 based on efficacy, safety and tolerability proven in clinical trials.” “This is a large-scale product capable of generating tens of billions of earnings in annual sales, and we intend to make further efforts to increase sales while strengthening the central nervous system (CNS) product line portfolio.
◇ 2023 Bio Pharmaceutical Job Fair opens on the 19th
▲ The ‘Korea Pharmaceutical and Bio Job Fair 2023’, jointly hosted by the Korea Pharmaceutical and Biotechnology Association, the Korea Health Industry Development Institute, and the Korea Human Resource Development Institute, will be held on the 19th.
‘Korea Bio Pharmaceutical Job Fair’ 2023, jointly hosted by the Korea Pharmaceutical and Biotechnology Association (Chairman Noh Yeon-hong), Korea Health Industry Development Organization (President Cha Sun-do), and Korea Human Resource Development Organization (President Bae ). Geum-joo), is held on the 19th.
The job fair, held in the first exhibition hall of the AT Center in Yangjae-dong, Seoul, begins with the opening ceremony at 10:30 am. On this day, the Ministry of Health and Welfare, the Ministry of Food and Drug Safety, the National Assembly, and heads of institutional organizations plan to visit the site and encourage job seekers.
The expo includes recruitment booths, an academy hall, a recruitment information hall, a career consultation hall, and a job mentoring hall. Host organizations such as the Korea Pharmaceutical and Biotechnology Association, the Korea Human Resource Development Institute for Health and Welfare, the Artificial Intelligence New Drug Development Support Center, and the Korea Health Industry Development Institute will present promotional halls.
On this day, 60 companies, including pharmaceutical and bio companies, digital health, and artificial intelligence, will set up recruitment booths and provide 1,103 consultations to job seekers visiting the site.
Seven institutions, including the Safety Assessment Research Institute, Sungkyunkwan University Graduate School of Pharmaceutical Industry Specialization, Dongguk University Graduate School of Pharmaceutical Bio-Industry Specialization, Yonsei University Pharmaceutical Industry Studies Convergence Program, Yonsei University K-NIBRT, Korea Regulatory Science Center, and Convergence College Biohealth Innovation, have an academy hall We form a team to discover talent.
13 companies are taking part in the recruitment briefing. In Hall A, recruitment briefings will be held at 10 am, starting with SK Bioscience, followed by Huons Group, HK Innoen, Daewoong Pharmaceutical, BC World Pharmaceutical, and GC Green Cross.
Between 1 pm and 2 pm, the Korea Human Resource Development Institute will host a special lecture on ‘Customized Strategies for Employment Success.’ Hall B is open from 10:40 am to 4:20 pm, and Daewon Pharmaceutical, Ildong Pharmaceutical, Medytox, Hitz, JW Group, Pharma Research, and Hanmi Pharmaceutical will hold recruitment information sessions.
The job mentoring center offers a mentoring program where job seekers can consult freely with current workers in the field they want to apply for. 20 people from 11 companies will serve as mentors, providing mentoring to 672 job seekers in all areas, including Research and Development, general management, production, sales and marketing.
The careers counseling center runs programs to help with career paths by providing the necessary information for employment in the pharmaceutical and bio industry.
As well as the on-site fair, attention is also given to the online-only recruitment center which will run until December 31 this year. The recruitment process for all posts takes place in the online recruitment centre.
As of the 15th, 68 companies had posted 320 job advertisements. It was calculated that around 1,700 people applied, with over 430,000 views recorded.
On the day of the job fair on the 19th, potential jobseekers will be given the ‘Pharmaceutical and Bioindustry Guide for Jobseekers’.
In addition, as an event to support jobseekers, food centers will be set up on site and free drink vouchers will be provided.
To enter the job fair on the day, you must apply in advance by registering as a member on the official job fair website.
When registering as a member, you will receive a certificate of participation (sent automatically by text) You can present the certificate of participation at the entrance on the day of the event.
Even if you were unable to apply in advance, you can enter by visiting the event site on the day and completing the application process at the self-registration desk.
Copyright © Medicine News Reproduction and redistribution prohibited.
#Green #Cross #Dengue #Fever #Rapid #Diagnostic #Kit #Obtained #Export #License
